PHN 121Alternative Names: PHN-121
Latest Information Update: 22 Sep 2015
At a glance
- Originator Industrial Technology Research Institute
- Developer PhytoHealth
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 29 Nov 2013 PhytoHealth terminates a phase I/II ENCHAMP trial in Hepatitis C in Taiwan (NCT01052090)
- 22 Oct 2008 Phase-I clinical trials in Hepatitis C treatment in Taiwan (unspecified route)